Madrigal Pharmaceuticals (NASDAQ: MDGL) entered into an exclusive global license agreement with Arrowhead Pharmaceuticals for the clinical‑stage siRNA asset ARO‑PNPLA3, a therapy that targets the PNPLA3 gene implicated in metabolic dysfunction‑associated steatohepatitis (MASH). Arrowhead will pay an upfront fee of $25 million, with potential milestone payments up to $975 million and future royalties on net sales, while Madrigal receives worldwide rights to develop, manufacture, and commercialize the asset.
The ARO‑PNPLA3 program is designed to silence the PNPLA3 I148M variant, a genetic driver present in roughly 30 % of moderate‑to‑advanced MASH patients and highly prevalent in the Hispanic population. Phase 1 data showed a 46 % reduction in liver fat, underscoring the therapeutic promise of this precision‑medicine approach.
Madrigal’s CEO Bill Sibold said, "MASH is a complex, heterogeneous disease and we believe patients will benefit from personalized treatment strategies targeting key genetic risk factors that drive disease progression and adverse outcomes." The deal complements Madrigal’s flagship therapy Rezdiffra, and the company plans to explore combination studies that could broaden the benefit profile for patients carrying the PNPLA3 variant.
Arrowhead’s CEO Christopher Anzalone noted, "Madrigal's leadership in the MASH space makes them a natural and attractive partner to advance ARO‑PNPLA3." The asset had previously been part of a partnership with Johnson & Johnson, which relinquished its rights in 2023, allowing Arrowhead to monetize the program through this licensing arrangement.
Market reaction to the announcement was positive. Arrowhead’s shares were near a 52‑week high of $76.76 on the day of the deal, and the company had delivered a 446 % return over the past year. Analyst coverage included JPMorgan’s overweight rating, Morgan Stanley’s upgrade, and TD Cowen’s buy recommendation. Madrigal’s stock had traded at $513.72 on May 1 and $520.79 on May 4, with a consensus moderate‑buy rating and a mean price target of $685.31 as of April 29.
The licensing agreement positions Madrigal to accelerate its MASH pipeline, offering a precision‑medicine asset that could be combined with Rezdiffra to address a broader patient population. The deal also provides Arrowhead with a significant revenue stream and the opportunity to focus on its core RNAi platform. Together, the transaction underscores the growing importance of targeted therapies in the expanding MASH market and highlights both companies’ strategic focus on precision medicine and pipeline expansion.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.